News Archive

Nov 2019

Nov 13, 2019 UK launch of VivaGel® BV

Oct 2019

Oct 31, 2019 DEP® gemcitabine outperforms Gemzar® in human pancreatic cancer model

Oct 30, 2019 Quarterly Cashflow Report

Oct 08, 2019 Starpharma to present at US Drug Delivery Conference

Sep 2019

Sep 26, 2019 FDA Authorisation of First-in-Human Clinical Trial with AstraZeneca’s DEP® product AZD0466

Sep 12, 2019 DEP® irinotecan synergistic with Lynparza® in refractory human colon cancer model

Sep 03, 2019 Starpharma’s VivaGel® BV regulatory approvals continue in Asia

Sep 03, 2019 VivaGel® BV regulatory approvals continue in Asia

Aug 2019

Aug 30, 2019 Update on Starpharma’s latest positive interim DEP® trial results, VivaGel® and upcoming milestones

Aug 29, 2019 Starpharma sees positive results in ovarian cancer treatment

Aug 29, 2019 Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model

Aug 28, 2019 Promising efficacy signals for Starpharma’s DEP® trials

Aug 28, 2019 Annual report and full year financial results

Aug 28, 2019 Promising efficacy signals observed in ongoing DEP® trials, including DEP® cabazitaxel escalation phase

Aug 15, 2019 First Asian Regulatory Approvals Received for VivaGel® BV

Aug 08, 2019 Starpharma commences phase 1/2 DEP® irinotecan trial

Jul 2019

Jul 31, 2019 Starpharma CEO speaks with Alan Kohler on The Constant Investor

Jul 16, 2019 Quarterly Cashflow Report

Jul 01, 2019 Shareholder Update July 2019

Jun 2019

Jun 27, 2019 VivaGel® BV launched in Europe

Jun 20, 2019 Starpharma presents at Macquarie Emerging Leaders Forum

Jun 12, 2019 US patent granted for DEP Bcl2/xL inhibitor conjugates

Jun 04, 2019 AstraZeneca inks new deal with Starpharma

Jun 04, 2019 Okamoto launches VivaGel® condom in Japan

Jun 03, 2019 Starpharma signs second oncology agreement with AstraZeneca

Jun 03, 2019 Starpharma signs second oncology agreement with AstraZeneca

May 2019

May 29, 2019 Starpharma presents at UBS Healthcare Conference

May 24, 2019 DEP® irinotecan combination outperforms in refractory human colon cancer model

May 23, 2019 Regulatory progress for VivaGel BV in the US

May 07, 2019 Starpharma to present at US Drug Delivery Conference

May 01, 2019 Starpharma presents at Macquarie Australia Conference

Apr 2019

Apr 29, 2019 Quarterly Cashflow Report

Apr 22, 2019 Starpharma on Channel Nine News (April 22, 2019)

Apr 16, 2019 Markets Live: Starpharma shares rise 13 per cent following Australian launch of VivaGel BV

Apr 16, 2019 First VivaGel BV launch globally in Australia by Aspen

Apr 11, 2019 Starpharma meets with US FDA to discuss VivaGel® BV

Apr 03, 2019 Starpharma Investor Presentation to Goldman Sachs Conference

Mar 2019

Mar 18, 2019 Shareholder Update March 2019

Mar 12, 2019 Starpharma receives $4.0M R&D tax incentive refund

Feb 2019

Feb 27, 2019 Starpharma Interim Report and Half-Year Financial Results

Jan 2019

Jan 30, 2019 Quarterly Cashflow Report

Jan 17, 2019 Shareholder Update January 2019

Jan 02, 2019 VivaGel® condom receives final regulatory approval in Japan